AIM: To investigate the efficacy and safety of @entity136 ( @entity14113 )-based combination chemotherapies for the treatment of advanced @entity1125 . METHODS: Clinical trials were identified by searching scientific literature databases (PubMed, EMBASE and the Cochrane Library) for studies published between 1975 and 2013. Two reviewers independently evaluated the relevant studies and manually searched references from these reports to locate additional eligible studies. The disease response and control rates, progression-free and overall survivals, and the grade 3-4 @entity137 were evaluated by a meta-analysis. Odds-ratios (ORs) of the disease response and control rates and grade 3-4 @entity137 , and the mean difference (MD) of both progression-free and overall survivals were calculated and used for statistical analysis. RESULTS: Seven randomized trials with a total of 858 @entity1 were selected and included in the final analysis. The studies were divided into subgroups based on the chemotherapy regimens, including @entity14113 -based and non- @entity14113 -based chemotherapies. The overall analyses revealed that the @entity1 treated with @entity14113 -based combination chemotherapy had significantly higher disease response rates [OR = 1.69, 95% confidence interval (CI): 1.17-2.43; P = 0.01], a longer progression-free survival (MD = 1.95, 95%CI: 0.90-3.00; P = 0.00) and a longer overall survival (MD = 1.85, 95%CI: 0.26-3.44; P = 0.02). A higher incidence of grade 3-4 hematological @entity137 , including @entity1431 (OR = 2.98, 95%CI: 1.44-6.20; P = 0.00), @entity417 (OR = 2.96, 95%CI: 1.79-4.92; P = 0.00) and @entity1398 (OR = 2.80, 95%CI: 1.39-5.64; P = 0.00) was found in the @entity14113 -based combination chemotherapy group compared with the @entity14113 monotherapy and non- @entity14113 -based chemotherapy groups. CONCLUSION: @entity14113 -based combination chemotherapy is a potential first-line treatment for advanced @entity1125 as a result of improved survival, though with additional @entity137 .

Efficacy and safety of XXXX -based chemotherapies in @entity1125 : a meta-analysis.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity14113 :: ('C056507', 'Chemical') :: ['Gem'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity1125 :: ('MESH:D001661', 'Disease') :: ['biliary tract cancer']
@entity136 :: (MESH:C056507,Chemical) :: ['gemcitabine']
